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1. Introduction 
The disruption of an organ’s blood supply is obligatory in clinical transplantation occurring 
at the time of organ procurement. During this ischaemic period complex pathophysiological 
changes occur within the organ that leave it primed in a pro-inflammatory state. Although 
the re-establishment of blood flow is essential to halt ongoing ischaemic damage, the organ 
incurs additional injury. This paradoxical response to reperfusion is known as ischaemia 
reperfusion injury (IRI).  
In deceased-donor transplantation, the haemodynamic instability and cytokine release 
associated with brain death augment the injury induced by ischaemia, which is more 
pronounced when donation occurs after cardiac death. Even with donation from a living 
donor there is a brief period of warm ischaemia after arterial cross-clamping. Following 
procurement, the donor organ is stored on ice as a means of slowing ischaemic injury. 
Although cold storage improves organ viability, a new set of complex processes is initiated 
by the combined effects of ischaemia and hypothermia. These ischaemic periods not only 
cause hypoxic/anoxic cell injury but lay the foundation for the augmented inflammatory 
response that occurs during reperfusion. 
IRI has a significant impact on both short and long-term transplant outcome. It is a principal 
cause of delayed graft function which is common in deceased-donor transplantation (Perico, 
Cattaneo et al. 2004). Delayed graft function occurs in up to 50% of recipients of kidneys 
following cardiac death of the donor and primary graft failure occurs in 10% of these 
transplants (Keizer, de Fijter et al. 2005). The inflammatory state incited during IRI enhances 
the immunogenicity of the graft leading to an increased incidence of rejection. The 
independent association between delayed graft function and graft loss has long been 
recognised and its influence is more pronounced with concomitant rejection (Halloran, 
Aprile et al. 1988; Shoskes and Cecka 1998). 
The mechanisms which underpin kidney IRI are complex and not yet fully defined. Both 
necrotic and apoptotic pathways of cell death are implicated and components of the 
inflammatory cascade, innate immune response, cellular infiltration and activation and the 
coagulation system are involved. In the kidney, endothelial cells, tubular epithelial cells and 
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infiltrating leukocytes all demonstrate specific responses during both ischaemic and 
reperfusion phases of injury, which amplify the tissue damage. Understanding the 
mechanisms that mediate IRI is a focus of significant scientific endeavour.  Therapeutics 
based on this research would not only improve the utility of transplantation from a finite 
donor pool by increasing short and long-term outcomes, but may have applications in 
numerous other clinical settings. The appeal of therapies that ameliorate the effects of IRI is 
more pronounced with the increasing use of organs from donors after cardiac death. 
2. Pathophysiological mechanisms in kidney IRI 
2.1 Apoptosis and necrosis 
Both apoptotic and necrotic cell death occur in kidney IRI. The tubular epithelial cell is 
particularly susceptible because of the low oxygen tension environment, the concentration of 
toxic substances and their high adenosine triphosphate (ATP) and oxygen requirements due to 
transporter activity. These factors confer greatest susceptibility to proximal tubular cells and 
the outer stripe of the S3 segment (outer medulla) of the kidney which has marginal basal 
oxygenation. More recently, the lysosomal degradation pathway of autophagy has an 
emerging role in kidney IRI. Tubular epithelial cells demonstrate autophagy as a response to 
injury but its role in reperfusion injury is still unclear (Koesters, Kaissling et al. 2010). 
Necrotic cell death is initiated by ATP depletion and mitochondrial damage that leads to 
impaired oxidative phosphorylation and the generation of reactive oxygen species (ROS). 
These ROS lead to a loss of cell adhesion to other cells and the extra-cellular matrix, damage 
the plasma membrane and intracellular membranes, and destabilise cytoskeletal proteins. 
These changes are associated with an increase in intracellular calcium and activation of the 
calcium-dependent cysteine protease calpain (Shi, Melnikov et al. 2000). 
Apoptosis, or programmed cell death, is ATP-dependent and results in the formation of 
apoptotic bodies by the condensation of cytoplasmic and nuclear components. These 
bodies induce phagocytosis of the apoptotic cell by surrounding macrophages.  
As opposed to necrosis which causes cell swelling, apoptosis results in shrinkage of the 
epithelial cells. While ATP depletion leads to necrotic cell death, the GTP (guanosine 
triphosphate) depletion noted in kidney IRI promotes apoptotic cell death (Kelly, Plotkin 
et al. 2001). Cells undergoing apoptosis but lacking the further ATP to proceed  
with the stages of programmed cell death may undergo secondary necrosis. This may 
explain why the apoptosis seen in IRI, unlike physiological apoptosis, is associated with 
inflammation. 
Both extrinsic and intrinsic pathways of apoptosis are implicated in IRI and there is 
considerable cross-talk between them. In kidney IRI receptors that are known to induce 
extrinsic apoptosis (termed ‘death-receptors’), such as the Fas receptor, are up-regulated 
(Del Rio, Imam et al. 2004). This signalling results in the activation of pro-caspase 8 via the 
formation of the death-inducing signalling complex (DISC). Caspase 8 subsequently 
activates caspase 3, 6 and 7 resulting in apoptosis. Inhibition of caspases is protective in IRI 
(Daemen, van 't Veer et al. 1999; Nicholson 2000). The intrinsic apoptotic pathway largely 
relates to mitochondrial function. The activation of pro-caspase 9, which triggers intrinsic 
apoptosis, is initiated by cytochrome C and the release of cytochrome C from mitochondria 
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is regulated by the Bcl-2 family of proteins (Gogvadze, Robertson et al. 2004). Over-
expression of the anti-apoptotic Bcl-2-like protein (BCL-xL) reduces cytochrome C release 
from mitochondria and is protective in IRI (Chien, Shyue et al. 2007). The tumour-
suppressor protein p53 is activated during hypoxia (by hypoxia inducible factor 1-). This 
amplifies the transcription of numerous pro-apoptotic genes such as caspases 6 and 7 (Yang, 
Kaushal et al. 2008) and Bcl-2. The p53 inhibitor pifithrin- protects in kidney IRI (Kelly, 
Plotkin et al. 2003) as does intravenous siRNA treatment directed against p53 in rats 
(Molitoris, Dagher et al. 2009). 
In kidney IRI extrinsic apoptotic, intrinsic apoptotic and regulatory pathways are activated. 
The outcome in terms of degree of apoptosis clearly relates to the balance between these 
complex and interacting systems. 
2.2 Inflammation and metabolism 
2.2.1 Toll-like receptors 
Toll-like receptors (TLRs) are a family of pattern recognition receptors. Endogenous ligands 
exposed during tissue injury such as heat shock proteins, host DNA, fibronectin and 
hyaluran can activate some TLRs.  Signal transduction from TLRs activates nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFB) leading to the activation of the innate 
immune system and the generation of pro-inflammatory cytokines. Renal tubular epithelial 
cells express TLR2 and TLR4 and their expression is up-regulated in IRI (Wolfs, Buurman et 
al. 2002). Both TLR2 and TLR4 bind heat-shock protein 60 and 70. TLR4 deficiency is 
protective in renal IRI and adoptive transfer experiments suggest that expression of TLR4 on 
renal tissue rather than bone-marrow derived cells mediates injury (Wu, Chen et al. 2007). 
Both deficiency and inhibition of TLR2 is protective in renal IRI models and TLR-2 mediated 
damage is, in part, dependent on the adapter protein MyD88 (Leemans, Stokman et al. 2005; 
Shigeoka, Holscher et al. 2007). 
2.2.2 Cytokines and chemokines 
IRI in the kidney leads to the generation of multiple pro-inflammatory cytokines such as  
IL-1, IL-6 and TNF (Takada, Nadeau et al. 1997) by infiltrating and resident leukocytes and 
endothelial cells. The manifestations of kidney IRI can often be observed systemically and in 
other organs and is explained, at least in part, by the release of cytokines. Inhibition of IL-1, 
IL-6 and IL-8 is protective in IRI; conversely, inhibition of IL-4 and IL-10 worsens renal 
injury (Deng, Kohda et al. 2001). 
Chemokines are a sub-family of cytokines that have an emerging role in kidney IRI. Their 
principal actions relate to leukocyte activation and chemotaxis. The renal expression of the 
CXC chemokine receptor 3 (CXCR3), which binds several chemokines, monokine, IFN-,  
IP-10 and CXCL11, is increased after IRI and mice deficient in CXCR3 were protected from 
an ischaemic insult (Fiorina, Ansari et al. 2006). CX3CL1, a leukocyte chemo-attractant and 
adhesion molecule, is expressed on T cells, NK cells and monocytes. Its expression is 
redistributed to the outer medulla in renal IRI and inhibition of its receptor, CX3CR1, 
attenuated fibrosis after IRI (Furuichi, Gao et al. 2006). Monocyte chemotactic protein 1 
(MCP-1) is up-regulated in kidney IRI and deficiency of its receptor (CCR2) attenuated 
injury and macrophage infiltration (Furuichi, Wada et al. 2003). 
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2.2.3 Complement 
The complement system has a pathogenic role early in renal IRI and all three pathways of 
activation (classical, alternative and mannose-binding lectin pathways) have been 
implicated (Farrar, Wang et al. 2004). Specific inhibition of, or deficiency in the alternative 
pathway protects kidneys in murine models of IRI (Thurman, Ljubanovic et al. 2003). 
Normally, epithelial cells lining the proximal tubules of the kidney express the complement 
inhibitor Crry on the basolateral membrane. After renal IRI, Crry is redistributed away from 
the basolateral surface of the cell, allowing deposition of C3 (the first component of the 
alternative pathway). Consistent with this finding, mice deficient in Crry are more 
susceptible to kidney IRI. C3a also has a role in the production of CXC chemokines by 
tubular epithelial cells observed after IRI (Thurman, Lenderink et al. 2007). C5a and the 
membrane attack complex (C5b-9) are implicated in kidney IRI and inhibition of C5a confers 
protection (Zhou, Farrar et al. 2000; Arumugam, Shiels et al. 2003; De Vries, Matthijsen et al. 
2003). Mannose-binding lectin recognizes several endogenous ligands in post-ischaemic 
renal tissue. These include ligands expressed on apoptotic and necrotic cells and exposed 
cytokeratin on hypoxic endothelial cells (Moller-Kristensen, Ip et al. 2006). The role of 
complement is further strengthened by the observation that mice deficient in the 
complement regulators CD55 and CD59 were more sensitive to renal IRI (Yamada, Miwa et 
al. 2004).  
2.2.4 Endothelial activation 
The endothelium plays a central role in IRI with effects on inflammation, permeability, 
coagulation and vascular tone. The endothelial cell subjected to ischaemia undergoes several 
changes in enzymatic activity, mitochondrial function, cytoskeletal structure, membrane 
transport, and antioxidant defences. The intensity of endothelial injury may be particularly 
important in determining the degree of chronic damage that a kidney will develop 
following IRI. Compared to tubular cells, the regenerative capacity of the renal endothelium 
is limited which leads to vascular dropout (Horbelt, Lee et al. 2007). Vascular endothelial 
growth factor (VEGF) inhibitors are induced in ischaemia and, in a rat model of IRI, VEGF 
treatment attenuated vascular dropout (Basile, Fredrich et al. 2008; Leonard, Friedrich et al. 
2008). 
Ischaemia activates the endothelium and promotes the expression of various pro-
inflammatory gene products such as cytokines (Pinsky, Yan et al. 1995) and adhesion 
molecules. More specifically, the expression of ICAM-1 (Kelly, Williams et al. 1996), P-
selectin (Takada, Nadeau et al. 1997) and E-selectin (Singbartl and Ley 2000) is up-regulated 
and antibody blockade of ICAM-1 significantly attenuated IRI in rats. 
Endothelium-dependent vasodilatation, mediated by nitric oxide (NO), is impaired in 
arterioles following IRI (Pang, Wu et al. 2000) and the disordered auto-regulation can persist 
for up to 1 week. In addition to vasodilatory effects, NO is both cytoprotective (antioxidant 
activity) and cytotoxic (by the production of peroxynitrite) and can inhibit neutrophil-
mediated injury. These varying effects, which make the precise role of NO in IRI difficult to 
define, are in part due to differences between the isoforms of the NO synthase. In ischaemia, 
due to endothelial damage there is a reduction in endothelial nitric oxide synthase (eNOS) 
and a relative increase in inducible NOS (iNOS) and this imbalance is considered to 
www.intechopen.com
 Ischaemia Reperfusion Injury in Kidney Transplantation 
 
177 
contribute to injury, in part, by enhancing the thrombogenic tendancy of the endothelium 
(Goligorsky, Brodsky et al. 2004). Both deficiency and inhibition of iNOS protect in kidney 
IRI (Noiri, Peresleni et al. 1996; Ling, Edelstein et al. 1999). Furthermore, a NO inhibitor 
worsened, and treatment with the NOS substrate, L-arginine, attenuated kidney IRI in rats 
(Ogawa, Nussler et al. 2001; Chander and Chopra 2005). 
The permeability of the endothelial barrier separating the capillary lumen from the 
interstitial space is increased in IRI. In vivo imaging studies suggest that this effect is 
maximal 24 hours after ischaemic injury and occurs within 2-4 hours (Sutton, Mang et al. 
2003). A loss in the integrity of adeherens junctions as shown by the delocalisation of the 
adhesion molecule cadherin between endothelial cells was noted. Thus, the increased 
vascular permeability predominantly relates to para-cellular, rather than trans-cellular 
pathways. A role for the matrix metalloproteinases 2 and 9 has been postulated as their 
activation correlates with microvascular permeability. In murine IRI, an inhibitor of matrix 
metalloproteinase (minocycline) attenuated microvascular permeability (Sutton, Kelly et al. 
2005). 
2.2.5 Adenosine generation and signalling  
Ischaemic injury results in the extrusion and transport of intra-cellular adenosine 
triphosphate (ATP) from injured or dying cells into the extra-cellular space. Here it 
undergoes serial hydrolysis by the ecto-enzyme CD39 (ectonucleoside-triphosphate-
diphosphohydrolase-1) generating adenosine diphosphate (ADP) and adenosine 
monophosphate (AMP). AMP is further hydrolysed by the ecto-enzyme CD73 (ecto-5’-
nucleotidase) generating adenosine (Zimmermann 1992; Kaczmarek, Koziak et al. 1996). The 
concentration of adenosine, which acts at 4 receptors, is therefore increased in ischaemia and 
is thought to provide adaptive responses to hypoxia and attenuate inflammation and 
apoptosis by several intra-cellular second messenger pathways. Conversely, signalling by 
ATP and ADP at P2 purinergic receptors have pro-inflammatory and pro-thrombotic effects.  
Although adenosine treatment has been shown to be protective in IRI models (Lee and 
Emala 2000), its extremely short half-life and systemic haemodynamic effects in vivo makes 
its clinical application difficult. 
Manipulating the metabolic pathway of adenosine generation can influence kidney IRI. 
Transgenic over-expression of CD39 was protective in both warm and cold kidney IRI 
models. This finding is supported by the protection conferred by treatment with Apyrase 
(which provides CD39 enzymatic activity) and the severe injury noted in mice deficient in 
CD39 (Lu, Rajakumar et al. 2008; Crikis, Lu et al. 2010). CD73 is up-regulated in ischaemia 
by hypoxia-inducible factor 1 (Thompson, Eltzschig et al. 2004) and is thought to be part of 
an innate protective mechanism during hypoxia. Although soluble CD73 (5’ nucleotidase) 
treatment was protective in a murine kidney IRI model, this is inconsistent with other 
studies demonstrating protection with CD73 deficiency or inhibition. This may relate to 
differences in the IRI models (Van Waarde, Stromski et al. 1989; Grenz, Zhang et al. 2007; 
Rajakumar, Lu et al. 2010). 
All four adenosine receptors are present in the kidney and expression is up-regulated by 
ischaemia. The precise localisation of each receptor has proven difficult but there is evidence 
that the A1 and A2B receptors are the dominant receptors in the pre-glomerular vasculature 
www.intechopen.com
 Organ Donation and Transplantation – Public Policy and Clinical Perspectives 
 
178 
(Jackson, Zhu et al. 2002) and that A2B receptor expression is more prominent on the renal 
vasculature than the tubular epithelial cells (Grenz, Osswald et al. 2008).  
A1 receptor activation has generally been protective in kidney IRI. Mice deficient in the A1 
receptor develop worse injury which is reversed by lentiviral reconstitution of the A1 
receptor in the kidney (Kim, Chen et al. 2009). A1 receptor agonist treatment was protective 
in a mouse kidney IRI model. Treatment conferred both acute and delayed protection, 
interestingly, by different signalling mechanisms (Joo, Kim et al. 2007). A2A receptor 
signalling is also protective in kidney IRI. Adoptive transfer experiments using wild-type 
and A2A receptor deficient mice in a kidney IRI model demonstrated A2A expression on 
bone-marrow derived cells mediates the protective effect (Day, Huang et al. 2003). 
Furthermore, a specific protective role for the A2A receptor on CD4+ T lymphocytes has 
been demonstrated (Day, Huang et al. 2006). Regulatory T lymphocytes have a protective 
role in kidney IRI and A2A receptor signalling is known to promote their expansion (Zarek, 
Huang et al. 2008). 
The A2B receptor has a lower affinity for adenosine than the other receptors and so may 
play a more prominent role in pathological states where there is increased adenosine 
generation. A2B receptor agonist treatment was protective in a mouse model of kidney IRI 
and a specific role in the protective phenomenon of ischaemic preconditioning was 
demonstrated. In contrast to the A2A receptor studies, adoptive transfer experiments 
localised the protective effect to A2B receptors on the renal parenchyma rather than 
infiltrating cells (Grenz, Osswald et al. 2008). The A3 receptor mediates injury in kidney IRI. 
Antagonist treatment protected, while agonist treatment worsened injury in a mouse model 
(Lee and Emala 2000). 
2.2.6 Oxidative stress 
In IRI, reperfusion is a trigger for the generation of reactive oxygen species (ROS) that 
mediate cell injury directly by lipid peroxidation of cellular membranes. ROS can increase 
activation, chemotaxis and endothelial adherence by stimulating adhesion molecules and 
cytokine gene expression through the activation of transcription factors such as NFκB 
(Toyokuni 1999). 
Haemoxygenase (HO) is an enzyme that degrades haem to produce carbon monoxide, 
biliverdin and bilirubin. Free haem can mediate cellular toxicity whilst the metabolic 
products are generally cytoprotective (Sikorski, Hock et al. 2004). Specifically, bilirubin is 
protective in a rat model of kidney IRI; HO-up-regulation confers cytoprotection in the 
kidney and carbon monoxide induces HIF- which up-regulates HO and over 100 other 
cytoprotective genes (Blydt-Hansen, Katori et al. 2003). Furthermore, carbon monoxide 
therapy was protective in a kidney transplant model (Neto, Nakao et al. 2006). Regulatory T 
cells have been shown to play a protective role in kidney IRI and HO expression on antigen-
presenting cells has been shown to be necessary for their full suppressive ability (George, 
Braun et al. 2008; Kinsey, Huang et al. 2010). 
The xanthine oxidase (XO) system is the major source of ROS production in mammals. 
During the ischaemic period, intracellular ATP is catabolised to hypoxanthine and hypoxic 
stress triggers the conversion of xanthine dehydrogenase (XDH) to the oxygen radical-
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producing XO (Younes, Schoenberg et al. 1984). During reperfusion, oxygen is reintroduced 
into the tissue, where it reacts with hypoxanthine and XO to produce a burst of oxygen free 
radicals; superoxide anion (O2-) and hydrogen peroxide (H2O2) (Harrison 2002). Under 
physiological conditions, the damaging effects of O2- are prevented in part by superoxide 
dismutase (SOD), which converts O2- to H2O2. During reperfusion of ischaemic tissues, the 
capacity of these antioxidant pathways is exceeded leading to cellular injury and death. 
Mice deficient in SOD3 were shown to have increased oxidative stress and tubular cast 
formation in IRI (Schneider, Sullivan et al. 2010). 
2.2.7 Peroxisome proliferator-activated receptors 
The family of peroxisome proliferator-activated receptors (PPARs) nuclear hormone 
receptors play a regulatory role in inflammatory responses, lipid metabolism, cellular 
differentiation and cell survival and have attracted increasing attention in IRI. PPAR 
deficient mice have worse injury in kidney IRI (Portilla, Dai et al. 2000) while treatment with 
PPAR- ligand or over-expression in the proximal tubules confers protection (Sivarajah, 
Chatterjee et al. 2002; Li, Nagothu et al. 2009). PPAR agonist treatment protects in kidney 
IRI and PPAR/ activity is also protective (Sivarajah, Chatterjee et al. 2003; Letavernier, 
Perez et al. 2005). 
2.3 Cellular mediators 
2.3.1 Neutrophils, macrophages, dendritic cells and natural killer cells 
Early infiltration of neutrophils into the post-ischaemic kidney has been demonstrated (Chiao, 
Kohda et al. 1997) and likely contributes to kidney IRI by the release of reactive oxygen species 
and proteases and by obstructing flow in the renal microvasculature. Inhibiting neutrophil 
infiltration is protective (Kelly, Williams et al. 1996) however only partial protection was 
observed with neutrophil blockade or depletion (Thornton, Winn et al. 1989). 
The role of macrophages in renal IRI is via the production of pro-inflammatory cytokines 
(IL-1, IL-6, IL-12p40/70, TNF) and activation of other leucocytes. Macrophages infiltrate 
the kidney early in IRI (within 1 hour) and particularly target the outer medulla. The 
infiltration is mediated by CCR2 and CX3CR1 signalling (Li, Huang et al. 2008; Oh, Dursun 
et al. 2008). Depletion of macrophages prior to IRI prevents injury and reconstitution 
restores it (Day, Huang et al. 2005). 
Dendritic cells (DC) form a link between the innate and adaptive arms of the immune 
system and are the most abundant resident leukocyte in the kidney interstitium. In 
particular, CD11c+MHC ClassII+ DC are abundant in the murine kidney suggesting an 
important role in regulating renal immunity and inflammation. Upon stimulation DCs 
becomes mature with phenotypic characteristics of increased expression of MHC Class II 
and co-stimulation molecules, the release pro-inflammatory factors and the ability to 
activate NKT cells (Dong, Swaminathan et al. 2005). Renal DC produce TNF-, IL-6, C-C 
motif chemokine 2 and C-C motif chemokine 5 in kidney IRI and the amount of TNF- 
produced after ischaemia is reduced after depletion of DCs (Dong, Swaminathan et al. 2007). 
Natural killer cells (NK) are cytotoxic lymphocytes without B or T cell receptors. Infiltration 
by NK cells has been noted by 4 hours and depletion of NK cells protects in kidney IRI in a 
perforin-dependent manner (Zhang, Wang et al. 2008). 
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2.3.2 CD4+ effector T lymphocytes 
Lymphocytes are the major mediators of adaptive immunity and so were initially not 
thought to contribute to IRI. Their significant role in IRI was, however, established with the 
demonstration that mice deficient in T cells are protected from IRI and the adoptive transfer 
of T cells restores injury (Burne-Taney, Yokota-Ikeda et al. 2005).  Further confirmation of 
the importance of T cells in the pathogenesis of IRI is that the use of CTLA4-Ig to block the 
B7-CD28 co-stimulation of T cells significantly attenuates renal dysfunction (Ysebaert, De 
Greef et al. 2004) as does use of a monoclonal antibody specific to B7 (De Greef, Ysebaert et 
al. 2001). The Th1 subset of T lymphocytes that produce IFN are deleterious, while IL4 
producing Th2 cells are protective in IRI (Yokota, Burne-Taney et al. 2003). Further 
confirmation of this is that adoptive transfer of CD4+ cells lacking CD28 are unable to 
restore this injury, as are CD4+ cells from IFN knock-out mice (Burne, Daniels et al. 2001). 
In murine renal IRI the number of invariant NKT cells (cells that possess a conserved 
invariant T cell receptor together with the NK cell marker NK1.1) is significantly increased 
at 3 hours of reperfusion following 30 minutes of ischaemia and inhibition or depletion of 
this cell type prevents injury. NKT cell activation was reported to contribute to kidney 
injury by mediating neutrophil IFNγ production (Li, Huang et al. 2007). 
The minor T cell subsets, the - T cell and the - T cell have a poorly understood role in 
kidney IRI. Deficiencies of these cell subsets have conferred protection (Savransky, Molls et 
al. 2006; Hochegger, Schatz et al. 2007). 
2.3.3. Regulatory T cells 
Regulatory T cells (Treg), known for their ability to suppress immune responsiveness, play a 
specific role in kidney IRI. Infiltration of Tregs was demonstrated 3 and 10 days after kidney 
IRI. Depletion of Tregs 24 hours after IRI resulted in increased tubular damage and cytokine 
production by infiltrating T effector cells. Infusion of Tregs resulted in early improvements 
in cytokine production and a late functional protective effect (Gandolfo, Jang et al. 2009). 
Correlating with this, Treg depletion was associated with an increased accumulation of 
neutrophils and macrophages, and increased inflammatory cytokine transcription, and Treg 
infusion prior to IRI attenuated inflammatory responses (Kinsey, Huang et al. 2010). 
2.3.4 B lymphocytes 
In kidney IRI the role of B lymphocytes remains unclear. They play a pathogenic role that 
relates to the production of natural antibodies, which develop without antigen stimulation. 
This is predominantly by B1 cells which are located in the pleural and peritoneal cavities. 
Depletion of peritoneal B1 cells reduced glomerular IgM deposition and protected mice 
from IRI. Conversely, the more abundant B2 cells likely play a protective role in kidney IRI 
mediated by IL-10 release (Renner, Strassheim et al. 2010). 
2.4 Coagulation 
Activation of the coagulation system has been noted in several IRI models. Ischaemia leads 
to a reduction in the expression of the anticoagulant thrombomodulin, the down-regulation 
of the endothelial protein C receptor (EPCR) and the up-regulation of tissue factor (Ogawa, 
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Shreeniwas et al. 1990). Thrombosis leads to further endothelial dysfunction and reduced 
tissue perfusion. Although anticoagulants such as heparin have been shown to be protective 
in IRI, the mechanism of protection relates to complement inhibition, the prevention of 
endothelial cell dysfunction and the release of vasoactive mediators from the endothelium, 
rather than direct anticoagulant effects (Kouretas, Kim et al. 1999). Kidney IRI was 
attenuated by soluble thrombomodulin treatment either before or after ischaemia. This was 
associated with reduced leukocyte adhesion and endothelial permeability and improved 
microvascular flow but was independent of its ability to generate activated protein C (APC) 
(Sharfuddin, Sandoval et al. 2009). Treatment with APC, which acts at the EPCR, is 
protective in a rat kidney IRI model. Again, the effect was considered to be independent of 
its anti-coagulant activity (Mizutani, Okajima et al. 2000). 
3. Therapeutic implications 
Based on recent advances in the understanding of the mechanistic basis of kidney IRI, 
several novel therapeutic approaches are being developed. Delineating the apoptotic cell 
death pathway has led to a pancaspase inhibitor and a p53 inhibitor that are currently in 
clinical trials for liver transplantation. The field of adenosine signalling is promising and an 
adenosine 2A receptor agonists is already available for myocardial diagnostic studies and 
selective adenosine 2B receptor agonists are being developed. The protective metabolic and 
anti-inflammatory effects of PPAR signalling have been demonstrated in murine kidney IRI 
models. Given thiazolidenediones (PPAR ligand) and fibrates (PPAR ligand) are already 
available, this demonstrates the capacity for basic research in kidney IRI to identify potential 
new applications for existing treatments. Similarly, statin (HMG-CoA reductase inhibitor) 
therapy is widely used for dyslipidaemia and preclinical studies suggest it is protective in 
kidney IRI (Yokota, O'Donnell et al. 2003). The mechanism of protection is unrelated to 
cholesterol lowering and may relate to caspase-3 mediated anti-apoptotic effects (Haylor, 
Harris et al. 2011). Donor treatment with simvastatin is currently under investigation 
(NCT01160978). 
Although erythropoietin treatment has a body of pre-clinical evidence suggesting protective 
effects (Sharples, Patel et al. 2004), clinical trials in both acute kidney injury and kidney 
transplantation have been disappointing to date (Endre, Walker et al. 2010; Martinez, Kamar 
et al. 2010). A greater understanding of the pathways of oxidative stress in kidney IRI have 
led to a focus on carbon monoxide. Given its systemic toxicity, donor compounds are being 
developed that may allow carbon monoxide release at the ischaemic tissue. Along a similar 
line, several anti-oxidant agents are currently being investigated. The significant role played 
by the complement system in several disease states has led to the development of treatments 
such as eculizumab (recombinant antibody targeting C5). This is being trialled in several 
clinical settings including kidney transplantation (Weitz, Amon et al. 2011). 
Modulating cellular interactions, such us the endothelial-leukocyte adhesion, is promising 
based on pre-clinical studies in kidney IRI. Antibody blockade of ICAM1 showed 
disappointing results in an early trial (Salmela, Wramner et al. 1999).  A recombinant 
blocking antibody to P-selectin has recently completed a phase 2 trial although an effect on 
delayed graft function has not yet been demonstrated (Osama Gaber, Mulgaonkar et al. 
2011). The emerging role of T lymphocytes in kidney IRI has meant that inhibiting early T 
lymphocyte activation is a focus of investigation. Anti-thymocyte globulin induction for 
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kidney transplantation has shown promising results and clinical trials are ongoing 
(NCT00733733/NCT01149993). Similarly, numerous agents that reduce T lymphocyte 
activation by blocking co-stimulation are under development. Belatacept, which prevents 
co-stimulation by binding to CD80 and CD86 on antigen-presenting cells was recently 
approved by the FDA for use in kidney transplant recipients (Vincenti, Dritselis et al. 2011). 
Cell-based therapies show significant promise. On a background of positive pre-clinical 
studies (Togel, Hu et al. 2005), a clinical trial of autologous mesenchymal stem cell infusion 
in kidney transplantation is underway (NCT00752479). Haemopoietic stem cells, which may 
promote endothelial/microvascular repair also show promise (Becherucci, Mazzinghi et al. 
2009). The recent pre-clinical finding that regulatory T cells protect in kidney IRI suggests 
ex-vivo expansion and infusion may also have therapeutic potential.  
In addition to the recognized protective effects of hypothermia, insights into IRI 
mechanisms may improve reperfusion injury following cold ischaemia by modifying organ 
preservation methods. The University of Wisconsin (UW) solution widely used for 
preservation contains anti-oxidant ingredients such as allopurinol and glutathione. It also 
contains adenosine which may mediate cytoprotective effects. The addition of lecithinized 
SOD to the cold ischaemia preservation fluid improved early inflammation and later 
proteinuria and apoptosis in a rat kidney transplant model (Nakagawa, Koo et al. 2002). 
Similarly, carbon monoxide supplementation to UW preservation fluid led to improved 
histological damage and inflammatory responses in a pig transplant model (Yoshida, Ozaki 
et al. 2010). As an example of perfusion mediated protection, Yamauchi et al showed that 
flushing with the fibrinolytic agent streptokinase conferred protection in a non-heart beating 
donor rat kidney transplant model (Yamauchi, Schramm et al. 2003). A current clinical trial 
includes an experimental arm with infusion of the donor kidney with thymoglobulin which 
may attenuate T lymphocyte mediated injury with reperfusion (NCT01149993). 
Brief periods of ischaemia can protect an organ from a subsequent ischaemic insult. This 
phenomenon is known as ischaemic preconditioning (IP) and was originally described in 
canine hearts (Murry, Jennings et al. 1986). Protection by IP in a murine model of renal IRI 
has been demonstrated using cycles of renal artery occlusion (Grenz, Eckle et al. 2007). 
Protection of an organ from an ischaemic insult is also observed when the cycles of short-
term ischaemia are applied to a different anatomical site. This phenomenon is termed 
remote ischaemic preconditioning (RIP). Renal protection by RIP has been reported by 
cycles of ischaemia in the contra-lateral kidney in mice (Park, Chen et al. 2001). Several 
studies in humans have demonstrated the clinical applicability of RIP. A recent study 
demonstrated that cycles of lower limb ischaemia led to reduced ischaemic kidney injury in 
patients undergoing cardiac surgery (Zimmerman, Ezeanuna et al. 2011). While the 
phenomenon may be applied to transplantation, research into the mechanisms mediating 
RIP should also provide targets for future therapeutic strategies. Regulatory T cells play a 
dominant role in IP (Kinsey, Huang et al. 2010) as do CD39, CD73 and adenosine A2B 
receptor signalling (Grenz, Zhang et al. 2007; Grenz, Zhang et al. 2007; Grenz, Osswald et al. 
2008). In various IRI models ATP-dependent potassium channels (Pell, Baxter et al. 1998), 
protein kinase C (Weinbrenner, Nelles et al. 2002), nitric oxide synthesis (Wang, Xu et al. 
2001), bradykinin, heat shock proteins (Patel, van de Poll et al. 2004), haemoxygenase-1 
(Amersi, Buelow et al. 1999) and TNF (Teoh, Leclercq et al. 2003) have all been implicated. 
Clinical trials of remote preconditioning in kidney transplantation are currently underway 
(NCT01395719, NCT01289548). 
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4. Conclusion 
Kidney ischaemia reperfusion injury is obligatory in transplantation. Given the significant 
impact of IRI on both short and long-term graft function, therapeutic strategies to minimise 
IRI are of considerable appeal. This is particularly relevant with the increasing utilisation of 
organs from extended-criteria/non-heart-beating donors. However, the pathophysiological 
mechanisms mediating kidney IRI are complex and involve the interaction of numerous 
biological systems. Novel insights regarding these interactions are leading to the 
development of applications to attenuate IRI in the fields of therapeutics, organ preservation 
and ischaemic preconditioning. 
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